Probiotics in Metabolic Disorder Treatment

Microbial consortia for effectively treating conditions related to metabolic disease by efficiently breaking down and metabolizing disease-associated substrates. The consortia contain a group of active microbes that degrade the substrate causing the disease, along with a supportive community of microbes that optimize the active microbes' growth and metabolism. The supportive community enhances characteristics like engraftment, biomass, stability of the active microbes. The consortium can degrade substrates like phenylalanine, tyrosine, bile acids, and pathogenic carbohydrates.

Source

Using inactivated Lactobacillus casei I0B-P9 and its postbiotics to reduce blood glucose and improve dyslipidemia in diabetics.

Source

A method for treating type 2 diabetes (T2D) by modulating a subject's microbiota composition away from that associated with a Western diet and toward one conferring the benefits of a plant-based diet. The method involves administering probiotics and prebiotics to improve the gut microbiome, with strains shown to be beneficial in studies of diabetes and obesity. The microbial compositions can be customized based on an individual's microbiome profile and contain specific bacteria and fungi identified from plants.

Source

Using a specific strain of Lactobacillus rhamnosus called CMU-pb-7 isolated from feces, to prepare blood lipid-lowering drugs. The strain can relieve impaired glucose tolerance caused by a high-fat diet in mice with hyperlipidemia, reduce the blood lipid level, enhance the antioxidant capacity of the liver tissue, and regulate the expression of key proteins of liver lipid metabolism to relieve fatty change caused by a high-fat diet.

Source

Food or pharmaceutical compositions with specific strains of lactic acid bacteria (Lactobacillus fermentum TSF331 and Lactobacillus reuteri TSR332) that can be used to reduce blood uric acid concentration. The compositions can be administered to help prevent and treat conditions like hyperuricemia and gout. The compositions contain strains that have been shown to degrade purine and lower uric acid levels.

Source

Compositions and methods for treating type 1 diabetes using genetically modified lactic acid bacteria expressing IL-2 and a type 1 diabetes-specific antigen. The bacteria are orally administered to deliver low-dose IL-2 and antigen to the gut mucosa, stimulating regulatory T cells to suppress autoimmunity and reverse established type 1 diabetes.

Source

Genetically engineered bacteria that can reduce hyperphenylalaninemia in mammals like humans. The bacteria are designed to produce a modified version of the enzyme phenylalanine ammonia lyase (PAL) that better metabolizes phenylalanine. This allows the bacteria to break down excess phenylalanine in the gut and reduce blood levels. It could offer a novel treatment option for phenylketonuria (PKU) and other disorders associated with high phenylalanine. The engineered bacteria may be orally administered to provide a long-term, natural protein-friendly approach to reducing phenylalanine.

Source

Compositions containing a mixture of microorganisms like bacteria, yeasts, and fungi for reducing blood urate levels as a treatment and prevention strategy for urate-related diseases like gout and hyperuricemia. The compositions aim to balance the gut microbiota by increasing uricase activity and reducing xanthine oxidase activity. This can be achieved using specific strains that inhibit xanthine oxidase and/or express uricase.

Source

A Lactobacillus plantarum strain that can lower blood glucose levels and has antioxidant activity. It's used in compositions like food, medical, and cosmetic products to help prevent and treat diabetes and provide antioxidant benefits. The strain, Lactobacillus plantarum MG4229, is isolated from food and has characteristics like acid and bile tolerance, hydrophobicity, and enzyme production.

Source

A composition for preventing and treating lipid-related metabolic diseases such as fatty liver, diabetes, and obesity. It contains Lactobacillus plantarum ATG-K2 or ATG-K6 strains isolated from fermented vegetables. The composition can be used as a health supplement or functional food to improve markers of liver health, lipid metabolism, obesity, and diabetes. It provides a natural and effective treatment option for lipid-related metabolic disorders.

Source

Using certain bacteria and their metabolites to prevent or treat inflammation-related diseases like diabetes, autoimmune conditions, cardiovascular disease, and inflammatory disorders. The specific bacteria are Desulfovibrio species like Desulfovibrio piger, and the metabolites include 6-bromotryptophan. Administering these agents can reduce inflammation and severity of these diseases.

Source

Probiotic compositions and methods for improving metabolic health and preventing obesity related disorders. The compositions contain specific strains of gut bacteria including Eubacterium eligens, Intestinimonas massiliensis, Prevotella copri, and certain Akkermansia species. Administering these compositions can help treat or prevent obesity, diabetes, metabolic syndrome and related conditions.

Source

Microorganisms and extracts thereof that reduce liver fat content, inhibit lipogenesis, promote fat oxidation, reduce body fat, and increase AMPK phosphorylation when contacted with liver or fat cells. The microorganisms are Lactobacillus strains LMT15-14 and LMT19-1.

Source

Feeding infants a nutritional composition containing Bifidobacterium breve and non-digestible oligosaccharides early in life to prevent metabolic disorders like fatty liver disease, hypercholesterolemia, and atherosclerosis later in life. The composition promotes healthy lipid metabolism and liver function when challenged with a high fat diet by modulating gene expression pathways. The Bifidobacterium breve probiotic and oligosaccharides combination can be added to infant formula to mimic breast milk benefits for long-term metabolic health.

Source

Early life nutritional intervention to prevent obesity, diabetes and chronic inflammation. Administering bifidobacterium breve and non-digestible oligosaccharides to infants results in lower insulin levels, improved insulin sensitivity, and reduced inflammation when challenged with a Western diet later in life. The combination programs infants to better withstand risks associated with a Western diet, preventing hyperinsulinemia, insulin resistance, diabetes, and chronic inflammation.

Source

A Lactobacillus Plantarum strain (Accession No. KCTC 14107BP) that can inhibit fat accumulation in white adipose tissue, brown adipose tissue, and liver tissue. The strain also reduces blood glucose levels, improves glucose tolerance, and ameliorates insulin resistance.

Source

Food and pharmaceutical compositions containing specific strains of lactic acid bacteria that can modulate blood glucose levels and help prevent and treat diabetes. The compositions contain strains of Lactobacillus reuteri, Lactobacillus salivarius, Lactobacillus acidophilus, and Lactobacillus johnsonii. Administering these compositions can help lower blood glucose levels. The strains have been deposited in culture collections.

Source

Using bacterial probiotics that produce AhR receptor agonists to prevent and treat metabolic syndrome and obesity. The probiotics stimulate the Aryl hydrocarbon receptor (AhR) pathway which is impaired in metabolic syndrome. AhR agonists improve weight, glucose control, and fatty liver disease in animal models of obesity. The agonists also show promise in human studies. The invention involves using AhR agonist-producing probiotics or AhR agonists themselves to activate the pathway and treat metabolic syndrome and obesity.

Source

Microbe-based therapies for treating disorders like neurological and metabolic conditions, by modulating the microbiome to produce beneficial metabolites like SCFAs. The therapies involve administering purified populations of microbes that increase butyrate production in the subject. The microbes can modulate neural, hormonal, and metabolic pathways to treat the disorders. The compositions can be administered orally in pill form and are useful after antibiotic treatments to restore a healthy microbiome. The compositions can be customized based on a subject's microbiome sequencing.

Source

Using the bacterium strain Pediococcus acidilactici to regulate blood glucose levels and prevent or treat hyperglycemia. Administering this bacterium orally in a composition as a probiotic has been shown to lower blood glucose levels and prevent hyperglycemia in animal models.

Source

A novel Lactobacillus fermentum strain (Accession No. KCTC 14106BP) that inhibits fat accumulation in white and brown adipose tissues, reduces liver weight and fat accumulation, lowers fasting blood glucose and improves glucose tolerance. The strain also increases anti-inflammatory macrophages and Treg cells in adipose tissue. This unique Lactobacillus fermentum strain shows potential for preventing and treating metabolic diseases like obesity, diabetes, and fatty liver.

Source

Composition and method for preventing and/or treating obesity, diabetes, hyperlipemia or hypercholesterolemia. The composition includes a propionic acid bacterium, such as Propionibacterium freudenreichii, that when ingested can promote propionic acid production in the intestine. Propionic acid has been shown to suppress weight gain and reduce body weight.

Source

Use of Lactobacillus plantarum L-137 in preventing, ameliorating, or treating metabolic syndrome. The composition containing Lactobacillus plantarum L-137 for preventing, ameliorating, or treating metabolic syndrome.

Source

Using bacterial strains to treat type 2 diabetes by leveraging the potential of the gut microbiome. The method involves administering an effective amount of bacterial strains associated with type 2 diabetes to a subject diagnosed with or at risk of developing the disease. The bacterial strains include Coprobacillus, Dorea longicatena, Eubacterium limosum, Hungatella hathewayi, Lachnospiraceae bacterium, and others.

Source

Using the Lactobacillus fermentum strain KCTC 14105BP to prevent or treat metabolic diseases like obesity, diabetes, hypertension, fatty liver etc. The strain reduces fat accumulation in adipose tissue and liver, lowers blood glucose levels, improves insulin sensitivity, and regulates adipokine secretion.

Source

A probiotic formulation for reducing uremic toxins, lowering cholesterol and triglycerides in patients with kidney dysfunction. The formulation contains specific bacteria species including Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus casei, Bifidobacterium longum, Bifidobacterium bifidum, Bifidobacterium breve or Bifidobacterium infantis, or Bacteroides species.

Source

An isolated strain of the probiotic bacteria Lactobacillus amylovorus, which can reduce trimethylamine (TMA) and trimethylamine-n-oxide (TMAO) levels in the blood when administered orally. High levels of TMA and TMAO are associated with diseases like kidney disease, diabetes, obesity, cardiovascular disease, and cancer. The strain, named LAM1345, can be used as a supplement or in pharmaceutical compositions to treat these conditions.

Source

A probiotic composition containing three strains of lactic acid bacteria that can reduce blood glucose and hemoglobin A1c levels when administered to alleviate type 1 diabetes. The composition includes Lactobacillus salivarius subsp. salicinius AP-32, Lactobacillus johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 in a specific ratio. Administering this probiotic mixture can reduce blood glucose and HbA1c levels in subjects with type 1 diabetes.

Source

Methods for treating obesity and food addiction by modulating gut microbiome composition using bacterial strains, such as Akkermansia, Bacteroides, Clostridiales, Ruminoccoccus, and Faecalibacterium, alone or in combination with drugs like naltrexone. The bacterial strains can be administered as pharmaceutical compositions or food supplements. The compositions are used to treat obesity and food addiction by correcting imbalances in the gut microbiome, which have been linked to these conditions.

Source

Composite probiotics made up of four strains of bacteria - Bifidobacterium adolescentis CCFM8630, Lactobacillus reuteri CCFM8631, Lactobacillus rhamnosus CCFM1044 and Lactobacillus casei CCFM711 - that work synergistically to alleviate metabolic syndrome symptoms like abnormal blood lipid, liver injury, inflammation and oxidative stress.

Source

Composition comprising a commensal gut bacteria like Bacteroides acidifaciens and intestinal alkaline phosphatase (IAP) taken together to treat metabolic disorders like obesity and diabetes.

Source

Composition for prevention and treatment of metabolic diseases (such as obesity, diabetes) and muscle diseases (such as atrophy, dystrophy) using vesicles derived from bacteria of the genus Lactobacillus. The vesicles are isolated from bacterial culture or food fermented with Lactobacillus species. Administering the vesicles orally activates AMPK in muscles and reduces body weight, food intake, and fasting blood sugar levels in animal models of obesity and diabetes.

Source

GABA-producing bacterial strain Lactobacillus brevis DPC6108 and its use in improving health through improving the gut microflora. The strain can convert monosodium glutamate (MSG) to gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter. It can improve insulin sensitivity, reduce adipose tissue, lower cholesterol, and increase luminal GABA in the small intestine when administered to mice. The strain could be used as a probiotic to treat metabolic diseases like obesity and diabetes.

Source

Using a specific bacterium that converts inositol to propionic acid to treat and prevent metabolic syndrome, insulin resistance, and related conditions. The bacterium is capable of converting inositol to propionic acid via a gene set encoding an inositol to propionic acid pathway. Administering the bacterium as a probiotic or symbiotic or using it as a therapeutic to increase propionic acid levels in the gut to improve insulin resistance and related metabolic disorders.

Source

Live bacteria that can treat metabolic disorders like hyperglycemia and diabetes. The bacteria, Streptococcus australis, when administered to subjects, has demonstrated therapeutic effects in improving glucose homeostasis and reducing blood glucose levels.

Source

Anti-obesity and blood glucose control probiotic compositions for preventing and treating obesity and related metabolic disorders like diabetes. The compositions contain specific ratios of six probiotic strains (B. breve, B. longum, S. thermophilus, L. acidophilus, L. casei, L. delbrueckii) obtained from a Dusp6-deficient mammal. Administering these compositions reduces body weight/fat and prevents weight gain in subjects.

Source

Probiotics isolated from feces of infants for inhibiting and preventing the progression of renal disease. The probiotics include a Lactobacillus acidophilus BP105 strain and a Lactobacillus salivarius BP121 strain. These strains have high indoxyl sulfate and p-cresol removal ability, phosphorus absorption ability, and short-chain fatty acid production ability. Administering them can reduce uremic toxins, calcium phosphate levels, and the progression of renal disease. The strains are used in compositions like foods, supplements, or drugs.

Source

Using isolated and purified microbes from the human microbiome to treat metabolic disorders such as diabetes and obesity. The microbial composition can contain specific microbes that provide therapeutic benefits.

Source

A next-generation probiotic strain, Akkermansia muciniphila EB-AMDK19, that inhibits inflammatory response, prevents obesity, and improves metabolic health. The strain reduces inflammatory cytokine release, inhibits adipocyte differentiation, increases tight junction protein expression, lowers blood glucose levels, prevents hyperlipidemia, increases appetite suppressing hormones, and reduces body fat. The strain is isolated from human feces and can be used in pharmaceuticals and foods.

Source

A probiotic composition for alleviating metabolic syndrome. The composition contains three specific strains of Bifidobacterium adolescentis, Lactobacillus reuteri, and Lactobacillus rhamnosus in a specific ratio. The probiotic composition has significantly better effects on reducing epididymal fat content, fasting blood glucose level, sugar tolerance, LDL cholesterol, and inflammatory factors compared to using the strains individually or in pairs.

Source

Pharmaceutical and food composition containing extracellular vesicles derived from Akkermansia muciniphila as an active ingredient for treating, preventing or alleviating a metabolic disease. The composition can prevent or treat diseases like obesity, diabetes, hyperlipidemia, and hypertension caused by a high fat diet.

Source

Engineering microbes to produce fatty acid ethanolamides (FAEs) like oleoylethanolamide using sugar feedstocks, and administering the FAE-producing microbes to subjects as a probiotic to treat conditions like obesity or chronic pain. The engineered microbes express enzymes like NAPE synthase and NAPE phospholipase that convert glucose to FAEs like oleoylethanolamide. The microbes are grown in bioreactors to produce surplus FAEs that can be isolated or used directly in a pharmaceutical composition.

Source

Restoring the efficacy of GLP-1 based drugs for controlling blood sugar in patients with type 2 diabetes who have become unresponsive to the therapy. The method involves administering Lactobacillus probiotic strains to restore the impaired gut-brain axis function that causes the unresponsiveness.

Source

Administering microbial strains and lipopolysaccharides for modulating the metabolome as a diagnostic tool for screening diseases and as a treatment for diseases. Administering specific microbial strains to a subject and measuring metabolite levels before and after to identify strains that modulate specific metabolites. This can be used to characterize individuals' metabolomes and identify diseases they are susceptible to, and treat or prevent those diseases by administering the appropriate strains.

Source

Using a specific strain of Bacteroides bacteria called Bacteroides cellulosilyticus to prevent and treat lipid metabolism related diseases like atherosclerosis, cardiovascular disease, and obesity. The bacteria can be formulated into a composition like a food or pharmaceutical product for administration. The Bacteroides cellulosilyticus reduces body weight, lowers blood lipids, relieves myocardial ischemia, and alleviates vascular lesions when fed to experimental subjects.

Source

Using the probiotic bacterium Parabacteroides goldsteinii, its metabolites or components within compositions to prevent and treat chronic kidney disease. Administering the Parabacteroides goldsteinii improves renal function and reduces kidney damage. It lowers the albumin-to-creatinine ratio and blood urea nitrogen levels. It also reduces glomerulus sclerosis and inflammation.

Source

Using Faecalibacterium bacteria to prevent or treat fat-related diseases like metabolic syndrome and non-alcoholic fatty liver disease. The bacteria can be administered by creating a pharmaceutical composition containing the bacteria or a processed product.

Source

Probiotics with modified carbohydrate metabolism to regulate carbohydrate absorption when consumed. The probiotics metabolize or modify carbohydrates in a way that reduces absorption by host subjects. This enables controlling body weight, treating carbohydrate metabolism disorders and modifying carbohydrate absorption. The probiotics can be made by stress-based directed evolution to find strains with altered carbohydrate processing.

Source

Combination treatments to improve treatment of metabolic disorders like diabetes and obesity in individuals with implanted gastrointestinal sleeves. The combination treatments involve giving metabolic drugs, performing bariatric procedures, or administering microbiota modulators alongside the sleeve implant. This improves metabolic disorder outcomes in patients with the devices.

Source

Lactobacillus strain KCCM 11826P with excellent phosphorus-absorbing ability. This strain can be used in pharmaceutical compositions and health food products to prevent and treat hyperphosphatemia in conditions like chronic kidney disease. The strain can inhibit intestinal phosphorus absorption as an alternative to calcium-based phosphorus binders.

Source